Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
acetaminophen, Activin, Adicet, adolescent, Adverum, altogether, analgesic, angina, anthony, antigen, argument, aspect, assign, assignment, ASU, ATTR, background, BAL, Banc, baricitinib, barring, bassler, bilateral, Bio, biotech, Bird, blackmail, BMR, bonnie, Brexit, Brolucizumab, Cabilly, CAF, CAPELLA, carcinoma, chosen, Cinqair, citrate, competitor, complication, concomitant, counterpart, crisaborole, CRL, Curascript, cyclosporine, de, Deutschland, differentiate, disc, DMC, Dupixent, EADV, East, EP, erythema, ESCAPE, ESR, Eucrisa, evidenced, exit, expedited, expert, expiry, Fibrodysplasia, FOP, France, futility, Galderma, gemcabene, Gemphire, grande, Greenburgh, heard, hematologic, hip, HoFH, Hollow, huda, HUMIRA, hyperlipidemia, hypoaesthesia, Immunex, inactivating, ingredient, intangible, Intellia, interchangeable, intravenously, iridocorneal, JAK, judgement, jury, Kevraza, Kevzara, KevzaraTM, kidney, killing, Le, lessee, Lessor, lipase, liver, Lymphoblastic, magazine, McKesson, McMaster, membrane, Memorandum, mental, microvascular, Middle, mild, moot, Mount, mutually, nonsteroidal, NPDR, NSAID, NY, occupy, oldest, Ontario, opioid, optic, outpatient, overwhelming, PANORAMA, panretinal, paper, paraesthesia, pathway, pcJIA, PDUFA, peripheral, permission, pose, predetermined, predominately, proceeding, Progressiva, provisional, PRP, Questionnaire, qw, ranked, ransom, rebalancing, redistribute, reexamination, referendum, regime, rentable, repeal, rest, resubmit, rinucumab, Rock, routine, RUBY, school, SD, simultaneously, Sleepy, sponsorship, stay, stayed, stopped, subpoena, subscale, susceptible, suspend, suspended, Talent, TBA, TCS, tofacitinib, traction, Trait, Transthyretin, treaty, trevogrumab, Tribunal, Troy, undergoing, Unlimited, unplanned, unstable, upheld, verdict, vi, vitrectomy, vivo, Winthrop, WOMAC, Xeljanz, zoghbi
Removed:
Affordable, annum, aptamer, ascertained, averaging, choice, choose, Columbia, copy, counterclaimed, criterion, DARPin, Denmark, desire, distributor, extraordinary, ezetimibe, Fovista, fundamental, genome, geographic, gouty, Idec, incumbent, inhibited, inside, lipid, MONO, MTX, myopia, nausea, occurred, Ophthotech, partially, pathologic, progression, prostate, reaction, receiver, recognizing, recombination, redeem, referenced, renewal, rental, repurchased, reserved, retroactively, shift, skeletal, slightly, survival, takeover, taxpayer, undisclosed, unwind, VENICE, warehousing
Filing tables
Filing exhibits
- 10-K Annual report
- 10.20.4 Goldman Sachs Termination Agreement, by and Between Goldman Sachs and Registrant
- 10.22.3 Citi 3RD Warrant Agreement, by and Between Citi and Registrant
- 10.22.4 Citi Termination Agreement, by and Between Citi and Registrant
- 10.24.5 Credit Suisse Termination Agreement, by and Between Credit Suisse and Registrant
- 10.26.3 Morgan Stanley Termination Agreement, by and Between Morgan Stanley & Registrant
- 10.35 Purchase Agreement, by & Among Bmr-landmark LLC, Bmr-landmark IV LLC, & REGN
- 21.1 Subsidiaries of Regeneron Pharmacuticals, Inc.
- 23.1 Consent of Pricewaterhousecoopers LLP
- 31.1 Certification of CEO Pursuant to Rule 13A-14(A)
- 31.2 Certification of CFO Pursuant to Rule 13A-14(A)
- 32 Certification of CEO and CFO Pursuant to 18 U.s.c. Section 1350
- Download Excel data file
- View Excel data file
Related press release
REGN similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S‑8 (Nos. 333-61132, 333-97375, 333-119257, 333-151941, 333-169569, 333-174863, 333-196799, and 333-198794) of Regeneron Pharmaceuticals, Inc., of our report dated February 9, 2017 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10‑K.
/s/ PricewaterhouseCoopers LLP
Florham Park, New Jersey
February 9, 2017